ORR in patient subgroups in the combined daratumumab 16 mg/kg group. Subgroup analysis of the overall best response in the 148 patients treated with daratumumab at a dose of 16 mg /kg. The dashed vertical line indicates 31.1%, which was the ORR in the total patient cohort. Exact 95% CIs are provided. International Staging System data are not available in GEN501 part 2. ALKY, alkylating agents, including autologous stem cell transplant; BORT, bortezomib; CARF, carfilzomib; CrCl, creatinine clearance; LEN, lenalidomide; POM, pomalidomide; THAL, thalidomide.